現代製藥(600420.SH)獲注射用米卡芬淨鈉藥品註冊批件
格隆匯12月3日丨現代製藥(600420.SH)公佈,公司於2019年11月23日披露了《關於控股子公司藥品通過註冊審批的公告》,公司控股子公司天偉生物通過國家藥品監督管理局網站獲悉,其藥品“注射用米卡芬淨鈉”通過註冊審批。
2019年12月3日天偉生物收到國家藥監局核准簽發的藥品註冊批件,現將有關“注射用米卡芬淨鈉”,批件號:2019S00598
天偉生物於2015年2月16日提交了藥品註冊申請並獲得受理,截至目前累計研發費用約人民幣3025.60萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.